Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Subodini Perampalam"'
Publikováno v:
Current biology : CB. 11(9)
The success of proteomics hinges in part on the development of approaches able to map receptors on the surface of cells. One strategy to probe a cell surface for the presence of internalized markers is to make use of Shiga-like toxin 1 (SLT-1), a rib
Autor:
Melissa Cheung, Subodini Perampalam, Reza Kiarash, Xin Wei, Leigh Revers, David Green, Erin Green, Jean Gariépy
Publikováno v:
Cancer Research. 70:4507-4507
Few treatment options exist for patients with metastatic melanoma. The standard treatment, dacarbazine (DTIC), shows low response rates ranging from 15% to 25 % with an 8-month median survival time. The development of targeted therapeutics with novel
An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo
Autor:
Reza Kiarash, Aws Abdul-Wahid, Xin Wei, Jean Gariépy, Melissa Cheung, David E Green, Leigh Revers, Subodini Perampalam
Publikováno v:
Molecular Cancer
Molecular Cancer, Vol 9, Iss 1, p 28 (2010)
Molecular Cancer, Vol 9, Iss 1, p 28 (2010)
Background Few treatment options exist for patients with metastatic melanoma, resulting in poor prognosis. One standard treatment, dacarbazine (DTIC), shows low response rates ranging from 15 to 25 percent with an 8-month median survival time. The de
Autor:
Cheung, Melissa C., Revers, Leigh, Subodini Perampalam, Xin Wei, Kiarash, Reza, Green, David E., Abdul-Wahid, Aws, Gariépy, Jean
Publikováno v:
Molecular Cancer; 2010, Vol. 9, Special section p1-14, 14p, 1 Diagram, 6 Graphs